Clinical trials: ABPA
Cystic Fibrosis,
Evaluation of Bronchial Inflammation in Allergic Bronchopulmonary Aspergillosis (ABPA)
Chronic bronchial inflammation is an important clinical feature in cystic fibrosis. Approximately 10% of patients with cystic fibrosis suffer from Allergic Bronchopulmonary Aspergillosis.
- Trial name
- ABPA (NCT00906568)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Allergic Bronchopulmonary Aspergillosis
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Itraconazole Administered as a Dry Powder for Inhalation (PUR1900) in Adult Asthmatic…
- Trial name
- NCT03960606
- Testing
- PUR1900
- Where
- 20 sites in United States, Australia and 3 more
- Volunteers
- 7 people
- Sponsor
- Pulmatrix Inc.
Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities.
- Trial name
- GLITZ (NCT05444946)
- Testing
- Prednisone tablet and Itraconazole, Oral itraconazole
- Where
- 2 sites in India
- Volunteers
- 104 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Allergic Bronchopulmonary Aspergillosis
A Randomized Trial of Prednisolone, Itraconazole, or Their Combination in Allergic Bronchopulmonary Aspergillosis
The investigators hypothesize that a combination of prednisolone and itraconazole would significantly reduce the exacerbation rate at one-year of patients with acute allergic bronchopulmonary aspergillosis (ABPA) compared to…
- Trial name
- PICA (NCT06174922)
- Testing
- Prednisolone, Itraconazole
- Where
- India
- Volunteers
- 300 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Allergic Bronchopulmonary Aspergillosis (ABPA)
Interest of IgE Directed Against Recombinant Antigens of Aspergillus Fumigatus in the Diagnosis of Allergic Bronchopulmonary Aspergillosis (ABPA)
Allergic Bronchopulmonary Aspergillosis is a rare pulmonary disease involving allergic mechanisms, which historically affects patients with asthma or cystic fibrosis only. It is a source of respiratory decompensation.
- Trial name
- BPCO (NCT07055230)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Rouen
Allergic Broncho-Pulmonary Aspergillosis
Protocol TARC-ABPA
The main objective of this study is to determine if a doubling of serum TARC (compared to baseline) is associated with the occurrence of exacerbations of ABPA. The secondary objectives of the study are : 1.
- Trial name
- NCT01710930
- Testing
- Study of predictive factors
- Where
- 2 sites in France
- Volunteers
- 29 people
- Sponsor
- Nantes University Hospital
Allergic Bronchopulmonary Aspergillosis
Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by a complex hypersensitivity response to antigens released by the fungus Aspergillus fumigatus.
- Trial name
- NCT00974766
- Testing
- Glucocorticoids
- Where
- India
- Volunteers
- 92 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
ABPA
Cytokine Profile of Allergic Bronchopulmonary Aspergillosis
The main aim of this study is to determine whether the levels of different inflammatory cytokines in the serum and BALF (bronchoalveolar lavage fluid) are relative to the severity and exacerbations of ABPA (allergic…
- Trial name
- NCT03643185
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning
Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction
To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.
- Conditions
- Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning, Multi-omics, Multicenter Study
- Trial name
- NCT07611838
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Qianfoshan Hospital
Cystic Fibrosis, Fungal Infection
Immune Profiles in CF Fungal Infection
This study is investigating the role of allergic (Th2) inflammation in patients with Cystic Fibrosis (CF) and history of fungal infection and/or Allergic Bronchopulmonary Aspergillosis.
- Conditions
- Cystic Fibrosis, Fungal Infection, Allergic Bronchopulmonary Aspergillosis
- Trial name
- NCT04476758
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
The purpose of this study is to see if giving people with CF and ABPA enough vitamin D to make their blood levels of the vitamin higher, will reduce the allergic response in their body and make the symptoms caused by ABPA better.
- Trial name
- NCT01222273
- Testing
- cholecalciferol (Vitamin D3)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Pittsburgh
ABPA
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
The goal of this clinical trial is to learn about PUR1900 as an inhaled, antifungal therapeutic for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
- Trial name
- NCT05667662
- Testing
- Itraconazole Powder
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 8 people
- Sponsor
- Pulmatrix Inc.
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07530770
- Testing
- Fasenra
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Allergic Bronchopulmonary Aspergilloses
A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus.
- Trial name
- NCT03133299
- Testing
- Glucocorticoids, Vitamin D
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis
iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine
This is a single center open-label feasibility trial involving a single study visit for participants. The purpose of the study is to demonstrate the feasibility of [68Ga]Ga-DFO-B PET/CT (gallium-68-deferoxamine) for the…
- Conditions
- Pulmonary Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
- Trial name
- MIRAGE (NCT06244979)
- Testing
- Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center
Allergic Bronchopulmonary Aspergillosis
A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
Inhaled amphotericin, a antifungal drug would decrease Aspergillus colonization and decrease the occurrence of exacerbations of Allergic Bronchopulmonary Aspergillosis (ABPA).
- Trial name
- NCT01857479
- Testing
- Inhaled budesonide, Inhaled amphotericin
- Where
- India
- Volunteers
- 21 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Allergic Bronchopulmonary Aspergillosis
Multicenter Registration Study on Allergic Bronchopulmonary Aspergillosis
To understand the current diagnosis and treatment status of ABPA patients, observe their clinical characteristics, prognosis, and treatment outcomes, and identify the relevant factors for poor prognosis in patients.
- Trial name
- NCT06645210
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University Third Hospital
Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD)
Immune Status and Disease Control of Inflammatory Airway Diseases
The goal of this study is to learn how the body's immune system affects disease control in people with different airway inflammatory diseases.We want to understand: 1.Whether specific immune cell patterns in the blood are linked…
- Conditions
- Airway Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Asthma (Diagnosis), Bronchiectasis
- Trial name
- ISDC-IAD (NCT07493629)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Ningbo University
ABPA, Allergic Bronchopulmonary Aspergillosis
A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA
To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Airway Clearance
- Trial name
- NCT07362667
- Testing
- The patients were treated with bronchoscopic airway clearance and amphotericin B spraying
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Qianfoshan Hospital